Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 2/20 | 0.50 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.41 |
| ▸ | ERN1 | O75460 | 3/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | BACE1 | P56817 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | KIF11 | P52732 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | SCN4A | P35499 | 1/20 | 0.37 |
| ▸ | APP | P05067 | 1/20 | 0.37 |
| ▸ | DAO | P14920 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.36 |
| ▸ | FEN1 | P39748 | 1/20 | 0.36 |
| ▸ | RXRA | P19793 | 1/20 | 0.36 |
| ▸ | RXRB | P28702 | 1/20 | 0.36 |
| ▸ | RXRG | P48443 | 1/20 | 0.36 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL663646 | 0.83 | CES2 (0.50) | CES2ERN1POLBMAPTBACE1 | |
| SCHEMBL6853258 | 0.83 | POLB (0.42) | CES2POLBMAPTBACE1KDM4E | |
| SCHEMBL4416163 | 0.81 | CES2 (0.47) | CES2HCAR1BACE1KDM4EKIF11 | |
| SCHEMBL333114 | 0.79 | IDO1 (0.42) | HCAR1ERN1KDM4EKIF11APP | |
| SCHEMBL153434 | 0.79 | CYP1A1 (0.44) | CES2POLBMAPTBACE1KDM4E | |
| SCHEMBL6852469 | 0.79 | APP (0.49) | ERN1KDM4EKIF11APP | |
| SCHEMBL3033291 | 0.79 | CYP1A1 (0.46) | CES2POLBMAPTBACE1KDM4E | |
| SCHEMBL7254716 | 0.79 | POLB (0.43) | CES2POLBMAPTBACE1KDM4E | |
| SCHEMBL4076004 | 0.79 | CES2 (0.46) | CES2HCAR1BACE1KDM4EEPHX2 | |
| SCHEMBL9996772 | 0.79 | CES2 (0.46) | CES2HCAR1BACE1KDM4EEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 395 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118459420-A | Thiazolinone compound containing multiple halogen atoms and preparation method thereof | 南京工业大学 | 2024-08-09 | — | — | CN | claimed |
| CN-118459422-A | Thiazole thiazolinone compound containing multiple halogen atoms and preparation method thereof | 南京工业大学 | 2024-08-09 | — | — | CN | claimed |
| CN-112639467-B | Platelet-like particles, method for producing the same, and quality control substance or calibrator containing the same | 深圳迈瑞生物医疗电子股份有限公司 | 2024-04-09 | — | — | CN | claimed |
| CN-115043737-B | Tetrahydrolinalool secondary amine compound, preparation method and weeding application thereof | 中国林业科学研究院林产化学工业研究所 | 2024-03-15 | — | — | CN | claimed |
| CN-115043737-A | Tetrahydroarylo secondary amine compound, preparation method and weeding application thereof | 中国林业科学研究院林产化学工业研究所 | 2022-09-13 | — | — | CN | claimed |
| CN-112639467-A | Platelet simulation particle, preparation method thereof and quality control substance or calibrator containing the simulation particle | 深圳迈瑞生物医疗电子股份有限公司 | 2021-04-09 | — | — | CN | claimed |
| WO-2020132906-A1 | PLATELET SIMULATION PARTICLE AND PREPARATION METHOD THEREFOR AND QUALITY CONTROL MATERIAL OR CALIBRATION MATERIAL CONTAINING SAME | 深圳迈瑞生物医疗电子股份有限公司 | 2020-07-02 | — | — | WO | claimed |
| US-20090197167-A1 | Fluorinated Additives For Lithium Ion Batteries | SOLVAY FLUOR GMBH (DE) | 2009-08-06 | — | — | US | claimed |
| EP-1938404-A1 | FLUORINATED ADDITIVES FOR LITHIUM ION BATTERIES | Solvay Fluor GmbH (DE) | 2008-07-02 | — | — | EP | claimed |
| WO-2007042471-A1 | FLUORINATED ADDITIVES FOR LITHIUM ION BATTERIES | SOLVAY FLUOR GMBH (DE) | 2007-04-19 | — | — | WO | claimed |
| US-6967197-B2 | Thiazepinyl hydroxamic acid derivatives as matrix metalloproteinase inhibitors | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-11-22 | — | — | US | claimed |
| EP-1390336-A1 | METHOD FOR PRODUCING AROMATIC ALDEHYDES AND KETONES BY THE CATALYTIC OXIDATION OF ALKYL-AROMATIC COMPOUNDS | DSM Fine Chemicals Austria Nfg GmbH & Co KG (AT) | 2004-02-25 | — | — | EP | claimed |
| US-20030134849-A1 | Thiazepinyl hydroxamic acid derivatives as matrix metalloproteinase inhibitors | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-07-17 | — | — | US | claimed |
| WO-2002096849-A1 | METHOD FOR PRODUCING AROMATIC ALDEHYDES AND KETONES BY THE CATALYTIC OXIDATION OF ALKYL-AROMATIC COMPOUNDS | DSM FINE CHEMICALS AUSTRIA NFG GMBH & CO KG (AT) | 2002-12-05 | — | — | WO | claimed |
| US-6331649-B1 | REDUCING AN OXIME BY CATALYTIC HYDROGENTATION IN SOLVENT CONTAINING AN ACID | CENTRAL GLASS COMPANY, LIMITED (JP) | 2001-12-18 | — | — | US | claimed |
| EP-0442340-B1 | Process for the preparation of an organolithium compound starting from 1,3-bis(trifluoromethyl)-benzene | HOFFMANN LA ROCHE (CH) | 1995-02-22 | — | — | EP | claimed |
| US-5162577-A | Chemical intermediates | HOFFMANN-LA ROCHE INC. (US) | 1992-11-10 | — | — | US | claimed |
| EP-0442340-A2 | Process for the preparation of an organolithium compound starting from 1,3-bis(trifluoromethyl)-benzene | F. HOFFMANN-LA ROCHE AG (CH) | 1991-08-21 | — | — | EP | claimed |
| US-4727079-A | Brain-specific dopaminergic activity involving dihydropyridine carboxamides, dihydroquinoline and isoquinoline carboxamides | UNIVERSITY OF FLORIDA (US) | 1988-02-23 | — | — | US | claimed |
| US-20250388585-A1 | PRMT5 INHIBITORS AND USES THEREOF | GILEAD SCIENCES INC (US) | 2025-12-25 | — | — | US | disclosed |
| US-20250353863-A1 | TRICYCLIC SPIROLACTAM COMPOUNDS WITH ANTIMYCOBACTERIAL ACTIVITY | INST NAT SANTE RECH MED (FR) | 2025-11-20 | — | — | US | disclosed |
| US-12448388-B2 | PRMT5 inhibitors and uses thereof | GILEAD SCIENCES, INC. (US) | 2025-10-21 | — | — | US | disclosed |
| EP-4570313-A2 | CYANOTRIAZOLE COMPOUNDS | Otsuka Pharmaceutical Co., Ltd. (JP) | 2025-06-18 | — | — | EP | disclosed |
| US-12325702-B2 | ATF6 inhibitors and uses thereof | ALTOS LABS, INC. (US) | 2025-06-10 | — | — | US | disclosed |
| US-20250136594-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2025-05-01 | — | — | US | disclosed |
| US-12268675-B2 | Diaryl substituted 6,5-fused ring compounds as C5aR inhibitors | CHEMOCENTRYX, INC. (US) | 2025-04-08 | — | — | US | disclosed |
| CN-119212699-A | NLRP3 inhibitors | PTC医疗公司 | 2024-12-27 | — | — | CN | disclosed |
| EP-4479045-A2 | INHIBITORS OF NLRP3 | PTC Therapeutics, Inc. (US) | 2024-12-25 | — | — | EP | disclosed |
| CN-111788185-B | Diaryl substituted 6,5 fused ring compounds as C5a inhibitors | 凯莫森特里克斯股份有限公司 | 2024-12-13 | — | — | CN | disclosed |
| EP-4469438-A1 | COMPOUNDS AND METHODS OF USE | Tango Therapeutics, Inc. (US) | 2024-12-04 | — | — | EP | disclosed |
| CN-119060036-A | ATF6 inhibitors and uses thereof | 阿尔托斯实验室公司 | 2024-12-03 | — | — | CN | disclosed |
| US-20240376110-A1 | PRMT5 INHIBITORS AND USES THEREOF | GILEAD SCIENCES, INC. | 2024-11-14 | — | — | US | disclosed |
| WO-2024220917-A1 | PRMT5 INHIBITORS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2024-10-24 | — | — | WO | disclosed |
| EP-3773563-B1 | PRODRUGS OF FUSED-BICYCLIC C5AR ANTAGONISTS | CHEMOCENTRYX INC (US) | 2024-10-16 | — | — | EP | disclosed |
| CN-114096552-B | With A2ASmall molecule compounds for adenosine receptor antagonism | 中国人民解放军军事科学院军事医学研究院 | 2024-09-27 | — | — | CN | disclosed |
| CN-112313224-B | ATF6 inhibitors and uses thereof | 阿尔托斯实验室公司 | 2024-08-13 | — | — | CN | disclosed |
| CN-114096551-B | With A2A2-Benzylidene hydrazino adenosines with adenosine receptor agonistic activity | 中国人民解放军军事科学院军事医学研究院 | 2024-08-13 | — | — | CN | disclosed |
| CN-118459422-A | Thiazole thiazolinone compound containing multiple halogen atoms and preparation method thereof | 南京工业大学 | 2024-08-09 | — | — | CN | disclosed |
| US-20240124434-A1 | ATF6 INHIBITORS AND USES THEREOF | ALTOS LABS, INC. | 2024-04-18 | — | — | US | disclosed |
| CN-112639467-B | Platelet-like particles, method for producing the same, and quality control substance or calibrator containing the same | 深圳迈瑞生物医疗电子股份有限公司 | 2024-04-09 | — | — | CN | disclosed |
| CN-115043737-B | Tetrahydrolinalool secondary amine compound, preparation method and weeding application thereof | 中国林业科学研究院林产化学工业研究所 | 2024-03-15 | — | — | CN | disclosed |
| EP-3728203-B1 | DIARYL SUBSTITUTED 6,5-FUSED RING COMPOUNDS AS C5aR INHIBITORS | CHEMOCENTRYX INC (US) | 2024-03-13 | — | — | EP | disclosed |
| US-20240009169-A9 | PPARG Modulators for the Treatment of Osteoporosis | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2024-01-11 | — | — | US | disclosed |
| CN-111954525-B | Prodrugs of fused bicyclic C5aR antagonists | 凯莫森特里克斯股份有限公司 | 2023-12-26 | — | — | CN | disclosed |
| CN-111788184-B | Diaryl substituted 5, 5-fused ring compounds useful as C5aR inhibitors | 凯莫森特里克斯股份有限公司 | 2023-12-22 | — | — | CN | disclosed |
| WO-2023159148-A2 | INHIBITORS OF NLRP3 | PTC THERAPEUTICS, INC. (US) | 2023-08-24 | — | — | WO | disclosed |
| WO-2023159148-A2 | INHIBITORS OF NLRP3 | PTC THERAPEUTICS, INC. (US) | 2023-08-24 | — | — | WO | disclosed |
| WO-2023146987-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023146987-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| EP-4219477-A1 | CYANOTRIAZOLE COMPOUNDS | Otsuka Pharmaceutical Co., Ltd. (JP) | 2023-08-02 | — | — | EP | disclosed |
| US-11664093-B2 | Extrapolative prediction of enantioselectivity enabled by computer-driven workflow, new molecular representations and machine learning | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2023-05-30 | — | — | US | disclosed |
| US-11664093-B2 | Extrapolative prediction of enantioselectivity enabled by computer-driven workflow, new molecular representations and machine learning | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2023-05-30 | — | — | US | disclosed |
| US-20230115912-A1 | DIARYL SUBSTITUTED 6,5-FUSED RING COMPOUNDS AS C5aR INHIBITORS | CHEMOCENTRYX, INC. | 2023-04-13 | — | — | US | disclosed |
| US-11608336-B2 | Prodrugs of fused-bicyclic C5aR antagonists | CHEMOCENTRYX, INC. (US) | 2023-03-21 | — | — | US | disclosed |
| US-20230072933-A1 | PPARG Modulators for the Treatment of Osteoporosis | SCRIPPS RESEARCH INST (US) | 2023-03-09 | — | — | US | disclosed |
| CN-111032658-B | 5-5 fused rings as C5a inhibitors | 凯莫森特里克斯股份有限公司 | 2022-12-20 | — | — | CN | disclosed |
| US-20220378816-A1 | 2-BENZYLIDENE HYDRAZINOADENOSINE COMPOUNDS HAVING A2A ADENOSINE RECEPTOR AGONISTIC ACTIVITY | ACADEMY OF MILITARY MEDICAL SCIENCES (CN) | 2022-12-01 | — | — | US | disclosed |
| US-20220380402-A1 | 6-HYDRAZINOADENOSINE COMPOUNDS WITH A2A ADENOSINE RECEPTOR AGONIST ACTIVITY | ACADEMY OF MILITARY MEDICAL SCIENCES (CN) | 2022-12-01 | — | — | US | disclosed |
| EP-3630774-B1 | 5-5 FUSED RINGS AS C5A INHIBITORS | CHEMOCENTRYX INC (US) | 2022-11-23 | — | — | EP | disclosed |
| US-11485737-B2 | Diaryl substituted 5,5-fused ring compounds as C5aR inhibitors | CHEMOCENTRYX, INC. (US) | 2022-11-01 | — | — | US | disclosed |
| US-11478460-B2 | Diaryl substituted 6,5-fused ring compounds as C5aR inhibitors | CHEMOCENTRYX, INC. (US) | 2022-10-25 | — | — | US | disclosed |
| US-11479553-B2 | 5-5 fused rings as C5a inhibitors | CHEMOCENTRYX, INC. (US) | 2022-10-25 | — | — | US | disclosed |
| CN-115043737-A | Tetrahydroarylo secondary amine compound, preparation method and weeding application thereof | 中国林业科学研究院林产化学工业研究所 | 2022-09-13 | — | — | CN | disclosed |
| EP-3988550-A1 | 6-HYDRAZINOADENOSINE COMPOUND HAVING A2A ADENOSINE RECEPTOR AGONIST ACTIVITY | Academy Of Military Medical Sciences (CN) | 2022-04-27 | — | — | EP | disclosed |
| EP-3988559-A1 | 2-BENZYLIDENE HYDRAZINOADENOSINE COMPOUNDS HAVING A2A ADENOSINE RECEPTOR AGNOSTIC ACTIVITY | Academy Of Military Medical Sciences (CN) | 2022-04-27 | — | — | EP | disclosed |
| US-20220064167-A1 | IMIDAZO-PYRAZOLE CARBOXAMIDE DERIVATIVES AS ANTICANCER AGENTS AND THE SYNTHESIS THEREOF | AVIDIN KFT. (HU) | 2022-03-03 | — | — | US | disclosed |
| CN-114127070-A | Having a2A6-hydrazinoadenosines with adenosine receptor agonist activity | 中国人民解放军军事科学院军事医学研究院 | 2022-03-01 | — | — | CN | disclosed |
| CN-114096552-A | Having a2ASmall molecule compounds with adenosine receptor antagonistic effect | 中国人民解放军军事科学院军事医学研究院 | 2022-02-25 | — | — | CN | disclosed |
| US-11174327-B2 | Method for producing modified polyvinyl alcohol resin | KURARAY CO., LTD. (JP) | 2021-11-16 | — | — | US | disclosed |
| US-20210221803-A1 | ATF6 INHIBITORS AND USES THEREOF | ALTOS LABS, INC. | 2021-07-22 | — | — | US | disclosed |
| US-20210221803-A1 | ATF6 INHIBITORS AND USES THEREOF | ALTOS LABS, INC. | 2021-07-22 | — | — | US | disclosed |
| US-20210106568-A1 | DIARYL SUBSTITUTED 6,5-FUSED RING COMPOUNDS AS C5aR INHIBITORS | CHEMOCENTRYX, INC. | 2021-04-15 | — | — | US | disclosed |
| US-20210106568-A1 | DIARYL SUBSTITUTED 6,5-FUSED RING COMPOUNDS AS C5aR INHIBITORS | CHEMOCENTRYX, INC. | 2021-04-15 | — | — | US | disclosed |
| CN-112639467-A | Platelet simulation particle, preparation method thereof and quality control substance or calibrator containing the simulation particle | 深圳迈瑞生物医疗电子股份有限公司 | 2021-04-09 | — | — | CN | disclosed |
| US-20210052612-A1 | PRODRUGS OF FUSED-BICYCLIC C5aR ANTAGONISTS | CHEMOCENTRYX, INC. | 2021-02-25 | — | — | US | disclosed |
| EP-3774782-A2 | ATF6 INHIBITORS AND USES THEREOF | Black Belt TX Ltd (GB) | 2021-02-17 | — | — | EP | disclosed |
| US-20210009594-A1 | 5-5 FUSED RINGS AS C5a INHIBITORS | CHEMOCENTRYX, INC. | 2021-01-14 | — | — | US | disclosed |
| US-20210009596-A1 | DIARYL SUBSTITUTED 5,5-FUSED RING COMPOUNDS AS C5aR INHIBITORS | CHEMOCENTRYX, INC. | 2021-01-14 | — | — | US | disclosed |
| US-20210009596-A1 | DIARYL SUBSTITUTED 5,5-FUSED RING COMPOUNDS AS C5aR INHIBITORS | CHEMOCENTRYX, INC. | 2021-01-14 | — | — | US | disclosed |
| WO-2020253867-A1 | SMALL-MOLECULE COMPOUND HAVING A2A ADENOSINE RECEPTOR ANTAGONISM | 中国人民解放军军事科学院军事医学研究院 | 2020-12-24 | — | — | WO | disclosed |
| WO-2020253872-A1 | 2-BENZYLIDENE HYDRAZINOADENOSINE COMPOUNDS HAVING A2A ADENOSINE RECEPTOR AGNOSTIC ACTIVITY | 中国人民解放军军事科学院军事医学研究院 | 2020-12-24 | — | — | WO | disclosed |
| WO-2020253870-A1 | 6-HYDRAZINOADENOSINE COMPOUND HAVING A2A ADENOSINE RECEPTOR AGONIST ACTIVITY | 中国人民解放军军事科学院军事医学研究院 | 2020-12-24 | — | — | WO | disclosed |
| US-10828285-B2 | Diaryl substituted 6,5-fused ring compounds as C5aR inhibitors | CHEMOCENTRYX, INC. (US) | 2020-11-10 | — | — | US | disclosed |
| US-10829485-B2 | ATF6 inhibitors and uses thereof | BLACK BELT TX LTD (GB) | 2020-11-10 | — | — | US | disclosed |
| US-10828285-B2 | Diaryl substituted 6,5-fused ring compounds as C5aR inhibitors | CHEMOCENTRYX, INC. (US) | 2020-11-10 | — | — | US | disclosed |
| US-10829485-B2 | ATF6 inhibitors and uses thereof | BLACK BELT TX LTD (GB) | 2020-11-10 | — | — | US | disclosed |
| US-10813939-B2 | Bromodomain inhibitor as adjuvant in cancer immunotherapy | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2020-10-27 | — | — | US | disclosed |
| US-10759807-B2 | Diaryl substituted 5,5-fused ring compounds as C5aR inhibitors | CHEMOCENTRYX, INC. (US) | 2020-09-01 | — | — | US | disclosed |
| US-10759807-B2 | Diaryl substituted 5,5-fused ring compounds as C5aR inhibitors | CHEMOCENTRYX, INC. (US) | 2020-09-01 | — | — | US | disclosed |
| US-10744117-B2 | PPARG modulators for the treatment of osteoporosis | THE SCRIPPS RESEARCH INSTITUTE (US) | 2020-08-18 | — | — | US | disclosed |
| US-20200234798-A1 | EXTRAPOLATIVE PREDICTION OF ENANTIOSELECTIVITY ENABLED BY COMPUTER-DRIVEN WORKFLOW, NEW MOLECULAR REPRESENTATIONS AND MACHINE LEARNING | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS | 2020-07-23 | — | — | US | disclosed |
| US-20200234798-A1 | EXTRAPOLATIVE PREDICTION OF ENANTIOSELECTIVITY ENABLED BY COMPUTER-DRIVEN WORKFLOW, NEW MOLECULAR REPRESENTATIONS AND MACHINE LEARNING | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS | 2020-07-23 | — | — | US | disclosed |
| WO-2020132906-A1 | PLATELET SIMULATION PARTICLE AND PREPARATION METHOD THEREFOR AND QUALITY CONTROL MATERIAL OR CALIBRATION MATERIAL CONTAINING SAME | 深圳迈瑞生物医疗电子股份有限公司 | 2020-07-02 | — | — | WO | disclosed |
| US-10683294-B2 | 5-5 fused rings as C5a inhibitors | CHEMOCENTRYX, INC. (US) | 2020-06-16 | — | — | US | disclosed |
| US-20200148702-A1 | COMPOSITIONS AND METHODS FOR TREATING NEOPLASIA, INFLAMMATORY DISEASE AND OTHER DISORDERS | DANA FARBER CANCER INST INC (US) | 2020-05-14 | — | — | US | disclosed |
| US-20200140578-A1 | METHOD FOR PRODUCING MODIFIED POLYVINYL ALCOHOL RESIN | KURARAY CO., LTD. (JP) | 2020-05-07 | — | — | US | disclosed |
| US-10626095-B2 | Cyanotriazole compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2020-04-21 | — | — | US | disclosed |
| EP-3630774-A1 | 5-5 FUSED RINGS AS C5a INHIBITORS | ChemoCentryx, Inc. (US) | 2020-04-08 | — | — | EP | disclosed |
| US-10450292-B2 | Inhibitors of bacterial RNA polymerase: arylpropanoyl, arylpropenoyl, and arylcyclopropanecarboxyl phloroglucinols | Rutgers, The State University of New Jersesy (US) | 2019-10-22 | — | — | US | disclosed |
| WO-2019195159-A1 | PRODRUGS OF FUSED-BICYCLIC C5aR ANTAGONISTS | CHEMOCENTRYX, INC. (US) | 2019-10-10 | — | — | WO | disclosed |
| US-20190300526-A1 | PRODRUGS OF FUSED-BICYCLIC C5aR ANTAGONISTS | CHEMOCENTRYX, INC. | 2019-10-03 | — | — | US | disclosed |
| US-20190300526-A1 | PRODRUGS OF FUSED-BICYCLIC C5aR ANTAGONISTS | CHEMOCENTRYX, INC. | 2019-10-03 | — | — | US | disclosed |
| US-10407441-B2 | Compositions and methods for treating neoplasia, inflammatory disease and other disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-09-10 | — | — | US | disclosed |
| US-20190192491-A1 | DIARYL SUBSTITUTED 6,5-FUSED RING COMPOUNDS AS C5aR INHIBITORS | CHEMOCENTRYX, INC. | 2019-06-27 | — | — | US | disclosed |
| US-20190192491-A1 | DIARYL SUBSTITUTED 6,5-FUSED RING COMPOUNDS AS C5aR INHIBITORS | CHEMOCENTRYX, INC. | 2019-06-27 | — | — | US | disclosed |
| US-20190194208-A1 | DIARYL SUBSTITUTED 5,5-FUSED RING COMPOUNDS AS C5aR INHIBITORS | CHEMOCENTRYX, INC. | 2019-06-27 | — | — | US | disclosed |
| US-20190194208-A1 | DIARYL SUBSTITUTED 5,5-FUSED RING COMPOUNDS AS C5aR INHIBITORS | CHEMOCENTRYX, INC. | 2019-06-27 | — | — | US | disclosed |
| US-20190023682-A1 | INHIBITORS OF BACTERIAL RNA POLYMERASE: ARYLPROPANOYL, ARYLPROPENOYL, AND ARYLCYCLOPROPANECARBOXYL PHLOROGLUCINOLS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2019-01-24 | — | — | US | disclosed |
| US-20180369196-A1 | PPARG Modulators for the Treatment of Osteoporosis | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2018-12-27 | — | — | US | disclosed |
| US-20180346471-A1 | 5-5 FUSED RINGS AS C5a INHIBITORS | CHEMOCENTRYX, INC. | 2018-12-06 | — | — | US | disclosed |
| WO-2018222601-A1 | 5-5 FUSED RINGS AS C5a INHIBITORS | CHEMOCENTRYX, INC. (US) | 2018-12-06 | — | — | WO | disclosed |
| US-10106492-B2 | Fluorinated carbonyl compounds comprising a triple bond, methods for their manufacture and uses thereof | SOLVAY SA (BE) | 2018-10-23 | — | — | US | disclosed |
| US-10016394-B2 | PPARG modulators for treatment of osteoporosis | THE SCRIPPS RESEARCH INSTITUTE (US) | 2018-07-10 | — | — | US | disclosed |
| US-9984878-B2 | Resist under layer film composition and patterning process | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2018-05-29 | — | — | US | disclosed |
| US-9969673-B2 | Process for the manufacture of 1, 1′-difluorosubstituted dialkyl carbonates, isomers thereof and electrolyte compositions containing them | SOLVAY S.A. (BE) | 2018-05-15 | — | — | US | disclosed |
| CN-104080780-B | Derivative, its preparation method and its purposes as solvent additive of the meldrum's acid of fluorination | 索尔维公司 | 2018-04-13 | — | — | CN | disclosed |
| EP-2788313-B1 | PROCESS FOR THE MANUFACTURE OF 1,1'-DIFLUOROSUBSTITUTED DIALKYL CARBONATES | SOLVAY (BE) | 2018-02-21 | — | — | EP | disclosed |
| US-9882198-B2 | High performance lithium battery electrodes by self-assembly processing | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2018-01-30 | — | — | US | disclosed |
| US-20170360801-A1 | BROMODOMAIN INHIBITOR AS ADJUVANT IN CANCER IMMUNOTHERAPY | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2017-12-21 | — | — | US | disclosed |
| US-20170360801-A1 | BROMODOMAIN INHIBITOR AS ADJUVANT IN CANCER IMMUNOTHERAPY | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2017-12-21 | — | — | US | disclosed |
| US-9825331-B2 | Fluorinated derivatives of meldrum's acid, a method for the preparation of the same, and their use as a solvent additive | SOLVAY SA (BE) | 2017-11-21 | — | — | US | disclosed |
| US-9815849-B2 | Compositions and methods for treating leukemia | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-11-14 | — | — | US | disclosed |
| US-9815849-B2 | Compositions and methods for treating leukemia | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-11-14 | — | — | US | disclosed |
| US-9789120-B2 | Male contraceptive compositions and methods of use | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-10-17 | — | — | US | disclosed |
| US-9789120-B2 | Male contraceptive compositions and methods of use | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-10-17 | — | — | US | disclosed |
| CN-104428941-B | The carbonyls of fluorination comprising three keys, its manufacture method and application thereof | 索尔维公司 | 2017-10-13 | — | — | CN | disclosed |
| EP-3219717-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING (R)-N-METHYLNALTREXONE | Progenics Pharmaceuticals, Inc. (US) | 2017-09-20 | — | — | EP | disclosed |
| US-9763956-B2 | Diagnostic and treatment methods in subjects having or at risk of developing resistance to cancer therapy | THE BROAD INSTITUTE, INC. (US) | 2017-09-19 | — | — | US | disclosed |
| US-9763956-B2 | Diagnostic and treatment methods in subjects having or at risk of developing resistance to cancer therapy | THE BROAD INSTITUTE, INC. (US) | 2017-09-19 | — | — | US | disclosed |
| WO-2017100645-A2 | INHIBITORS OF BACTERIAL RNA POLYMERASE: ARYLPROPANOYL, ARYLPROPENOYL, AND ARYLCYCLOPROPANECARBOXYL PHLOROGLUCINOLS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2017-06-15 | — | — | WO | disclosed |
| US-20170145013-A1 | DIHYDROPTERIDINONE DERIVATIVES AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-05-25 | — | — | US | disclosed |
| US-20170143700-A1 | SYNTHESIS OF (R)-N-METHYLNALTREXONE | PROGENICS PHARMACEUTICALS, INC. (US) | 2017-05-25 | — | — | US | disclosed |
| US-9597327-B2 | Synthesis of (R)-N-methylnaltrexone | PROGENICS PHARMACEUTICALS, INC. (US) | 2017-03-21 | — | — | US | disclosed |
| US-9567301-B2 | Pyrrol-1-yl benzoic acid derivatives useful as myc inhibitors | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-02-14 | — | — | US | disclosed |
| US-9567301-B2 | Pyrrol-1-yl benzoic acid derivatives useful as myc inhibitors | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-02-14 | — | — | US | disclosed |
| US-20170035730-A1 | PPARG MODULATORS FOR TREATMENT OF OSTEOPOROSIS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2017-02-09 | — | — | US | disclosed |
| US-20170029437-A1 | Compositions and Methods for Treating Neoplasia, Inflammatory Disease and Other Disorders | NATIONAL INSTITUTES OF HEALTH- DIRECTOR DEITR | 2017-02-02 | — | — | US | disclosed |
| US-20170029437-A1 | Compositions and Methods for Treating Neoplasia, Inflammatory Disease and Other Disorders | NATIONAL INSTITUTES OF HEALTH- DIRECTOR DEITR | 2017-02-02 | — | — | US | disclosed |
| EP-2785703-B1 | 5-Fluorinated derivatives of Meldrum's acid (5-fluoro-1,3-dioxane-4,6-dione derivatives), methods for their preparation and their use as solvent additives in lithium ion batteries. | SOLVAY (BE) | 2017-01-11 | — | — | EP | disclosed |
| US-9540320-B2 | — | — | 2017-01-10 | — | — | US | disclosed |
| US-9540320-B2 | — | — | 2017-01-10 | — | — | US | disclosed |
| EP-2873110-B1 | FLUORINATED CARBONYL COMPOUNDS COMPRISING A TRIPLE BOND, METHODS FOR THEIR MANUFACTURE AND USES THEREOF | SOLVAY (BE) | 2016-12-21 | — | — | EP | disclosed |
| US-20160342088-A1 | RESIST UNDER LAYER FILM COMPOSITION AND PATTERNING PROCESS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2016-11-24 | — | — | US | disclosed |
| US-20160317547-A1 | Male Contraceptive Compositions And Methods Of Use | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-11-03 | — | — | US | disclosed |
| US-20160317547-A1 | Male Contraceptive Compositions And Methods Of Use | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-11-03 | — | — | US | disclosed |
| US-20160229816-A1 | CYANOTRIAZOLE COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2016-08-11 | — | — | US | disclosed |
| EP-3022199-A1 | CYANOTRIAZOLE COMPOUNDS | Otsuka Pharmaceutical Co., Ltd. (JP) | 2016-05-25 | — | — | EP | disclosed |
| WO-2016069949-A1 | COMPOSITIONS AND FORMULATIONS OF METHYLERTHRITOL PHOSPHATE PATHWAY INHIBITORS AND USES THEREOF | VIRGINIA TECH INTELLECTUAL PROPERTIES, INC. (US) | 2016-05-06 | — | — | WO | disclosed |
| US-9320741-B2 | Compositions and methods for treating neoplasia, inflammatory disease and other disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-04-26 | — | — | US | disclosed |
| US-9320741-B2 | Compositions and methods for treating neoplasia, inflammatory disease and other disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-04-26 | — | — | US | disclosed |
| US-9301962-B2 | Male contraceptive compositions and methods of use | BAYLOR COLLEGE OF MEDICINE (US) | 2016-04-05 | — | — | US | disclosed |
| US-9301962-B2 | Male contraceptive compositions and methods of use | BAYLOR COLLEGE OF MEDICINE (US) | 2016-04-05 | — | — | US | disclosed |
| WO-2015161108-A1 | PPARG MODULATORS FOR TREATMENT OF OSTEOPOROSIS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2015-10-22 | — | — | WO | disclosed |
| US-9164376-B2 | Patterning nano-scale patterns on a film comprising unzipping copolymers | GLOBALFOUNDRIES INC. (KY) | 2015-10-20 | — | — | US | disclosed |
| US-20150290187-A1 | SYNTHESIS OF (R)-N-METHYLNALTREXONE | Progenics Pharmaceuticals., Inc. | 2015-10-15 | — | — | US | disclosed |
| US-20150291521-A1 | PYRROL-1-YL BENZOIC ACID DERIVATIVES USEFUL AS MYC INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. | 2015-10-15 | — | — | US | disclosed |
| US-20150291521-A1 | PYRROL-1-YL BENZOIC ACID DERIVATIVES USEFUL AS MYC INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. | 2015-10-15 | — | — | US | disclosed |
| US-20150221929-A1 | High Performance Lithium Battery Electrodes By Self-Assembly Processing | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2015-08-06 | — | — | US | disclosed |
| US-20150191423-A1 | FLUORINATED CARBONYL COMPOUNDS COMPRISING A TRIPLE BOND, METHODS FOR THEIR MANUFACTURE AND USES THEREOF | SOLVAY SA (BE) | 2015-07-09 | — | — | US | disclosed |
| US-9073858-B2 | Methods of targeted drug development | Errico, Joseph P. (US) | 2015-07-07 | — | — | US | disclosed |
| US-9073858-B2 | Methods of targeted drug development | Errico, Joseph P. (US) | 2015-07-07 | — | — | US | disclosed |
| US-9073858-B2 | Methods of targeted drug development | Errico, Joseph P. (US) | 2015-07-07 | — | — | US | disclosed |
| US-20150150885-A1 | Compositions and Methods for Treating Neoplasia, Inflammatory Disease and Other Disorders | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-06-04 | — | — | US | disclosed |
| US-20150150885-A1 | Compositions and Methods for Treating Neoplasia, Inflammatory Disease and Other Disorders | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-06-04 | — | — | US | disclosed |
| EP-2873110-A1 | FLUORINATED CARBONYL COMPOUNDS COMPRISING A TRIPLE BOND, METHODS FOR THEIR MANUFACTURE AND USES THEREOF | SOLVAY SA (BE) | 2015-05-20 | — | — | EP | disclosed |
| CN-104428941-A | Fluorinated carbonyl compounds comprising a triple bond, methods for their manufacture and uses thereof | SOLVAY | 2015-03-18 | — | — | CN | disclosed |
| US-8981083-B2 | Compositions and methods for treating neoplasia, inflammatory disease and other disorders | DANA FARBER CANCER INSTITUTE, INC. (US) | 2015-03-17 | — | — | US | disclosed |
| US-8981083-B2 | Compositions and methods for treating neoplasia, inflammatory disease and other disorders | DANA FARBER CANCER INSTITUTE, INC. (US) | 2015-03-17 | — | — | US | disclosed |
| US-20150057303-A1 | SYNTHESIS OF (R)-N-METHYLNALTREXONE | PROGENICS PHARMACEUTICALS, INC. (US) | 2015-02-26 | — | — | US | disclosed |
| US-8957093-B2 | N-biphenylmethylindole modulators of PPARG | THE SCRIPPS RESEARCH INSTITUTE (US) | 2015-02-17 | — | — | US | disclosed |
| WO-2015008872-A1 | CYANOTRIAZOLE COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-01-22 | — | — | WO | disclosed |
| US-20140342221-A1 | PROCESS FOR THE MANUFACTURE OF 1, 1'-DIFLUOROSUBSTITUTED DIALKYL CARBONATES, ISOMERS THEREOF AND ELECTROLYTE COMPOSITIONS CONTAINING THEM | SYENSQO SA (BE) | 2014-11-20 | — | — | US | disclosed |
| US-20140322618-A1 | FLUORINATED DERIVATIVES OF MELDRUM'S ACID, A METHOD FOR THE PREPARATION OF THE SAME, AND THEIR USE AS A SOLVENT ADDITIVE | SOLVAY SA (BE) | 2014-10-30 | — | — | US | disclosed |
| EP-2788313-A1 | PROCESS FOR THE MANUFACTURE OF 1, 1'-DIFLUOROSUBSTITUTED DIALKYL CARBONATES, ISOMERS THEREOF AND ELECTROLYTE COMPOSITIONS CONTAINING THEM | Solvay SA (BE) | 2014-10-15 | — | — | EP | disclosed |
| EP-2785703-A1 | FLUORINATED DERIVATIVES OF MELDRUM'S ACID, A METHOD FOR THE PREPARATION OF THE SAME, AND THEIR USE AS A SOLVENT ADDITIVE | Solvay SA (BE) | 2014-10-08 | — | — | EP | disclosed |
| CN-104080780-A | Fluorinated derivatives of Meldrum's acid, a method for the preparation of the same, and their use as a solvent additive | SOLVAY | 2014-10-01 | — | — | CN | disclosed |
| CN-103987691-A | Process for the manufacture of 1,1'-difluorosubstituted dialkyl carbonates, isomers thereof and electrolyte compositions containing them | SOLVAY | 2014-08-13 | — | — | CN | disclosed |
| US-20140194439-A1 | METHODS OF TARGETED DRUG DEVELOPMENT | Errico, Joseph P. (US) | 2014-07-10 | — | — | US | disclosed |
| US-20140194439-A1 | METHODS OF TARGETED DRUG DEVELOPMENT | Errico, Joseph P. (US) | 2014-07-10 | — | — | US | disclosed |
| US-20140194439-A1 | METHODS OF TARGETED DRUG DEVELOPMENT | Errico, Joseph P. (US) | 2014-07-10 | — | — | US | disclosed |
| US-8772277-B2 | Nitrogen-containing heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-07-08 | — | — | US | disclosed |
| US-20140163069-A1 | COMPOSITIONS OF TARGETED DRUG DEVELOPMENT | Errico, Joseph P. (US) | 2014-06-12 | — | — | US | disclosed |
| US-20140163069-A1 | COMPOSITIONS OF TARGETED DRUG DEVELOPMENT | Errico, Joseph P. (US) | 2014-06-12 | — | — | US | disclosed |
| US-20140163069-A1 | COMPOSITIONS OF TARGETED DRUG DEVELOPMENT | Errico, Joseph P. (US) | 2014-06-12 | — | — | US | disclosed |
| CN-103636052-A | Lithium air battery cell | SOLVAY | 2014-03-12 | — | — | CN | disclosed |
| EP-2702631-A1 | LITHIUM AIR BATTERY CELL | Solvay SA (BE) | 2014-03-05 | — | — | EP | disclosed |
| WO-2014027003-A1 | USE OF LOW CONCENTRATIONS OF FLUORINATED ORGANIC COMPOUNDS AS SOLVENT ADDITIVES | SOLVAY SA (BE) | 2014-02-20 | — | — | WO | disclosed |
| US-20140045078-A1 | LITHIUM AIR BATTERY CELL | SOLVAY SA (BE) | 2014-02-13 | — | — | US | disclosed |
| WO-2014009377-A1 | FLUORINATED CARBONYL COMPOUNDS COMPRISING A TRIPLE BOND, METHODS FOR THEIR MANUFACTURE AND USES THEREOF | SOLVAY SA (BE) | 2014-01-16 | — | — | WO | disclosed |
| US-20140011862-A1 | Compositions and Methods for Treating Leukemia | COLD SPRING HARBOR LABORATORY (US) | 2014-01-09 | — | — | US | disclosed |
| US-20140011862-A1 | Compositions and Methods for Treating Leukemia | COLD SPRING HARBOR LABORATORY (US) | 2014-01-09 | — | — | US | disclosed |
| US-8618302-B2 | Methods and compositions of targeted drug development | Errico, Joseph P. (US) | 2013-12-31 | — | — | US | disclosed |
| US-20130323286-A1 | SYNTHESIS OF R-N-METHYLNALTREXONE | PROGENICS PHARMACEUTICALS, INC. (US) | 2013-12-05 | — | — | US | disclosed |
| WO-2013174697-A1 | USE OF FLUORINATED 2 -METHOXYMALONIC ACID ESTERS IN ELECTROLYTE OR SOLVENT COMPOSITIONS | SOLVAY SA (BE) | 2013-11-28 | — | — | WO | disclosed |
| EP-2667444-A1 | Use of fluorinated 2-methoxymalonic acid esters in electrolyte or solvent compositions | SOLVAY SA (BE) | 2013-11-27 | — | — | EP | disclosed |
| US-8574815-B2 | Patterning nano-scale patterns on a film comprising unzipping copolymers | INTERNATIONAL BUSINESS MACHINES CORPORATION (US) | 2013-11-05 | — | — | US | disclosed |
| US-20130252331-A1 | COMPOSITIONS AND METHODS FOR MODULATING METABOLISM | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2013-09-26 | — | — | US | disclosed |
| US-20130252331-A1 | COMPOSITIONS AND METHODS FOR MODULATING METABOLISM | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2013-09-26 | — | — | US | disclosed |
| US-20130210813-A1 | Male Contraceptive Compositions and Methods of Use | DANA-FARBER CANCER INSTITUTE, INC. | 2013-08-15 | — | — | US | disclosed |
| US-20130210813-A1 | Male Contraceptive Compositions and Methods of Use | DANA-FARBER CANCER INSTITUTE, INC. | 2013-08-15 | — | — | US | disclosed |
| US-20130184264-A1 | Compositions And Methods For Treating Neoplasia, Inflammatory Disease And Other Disorders | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2013-07-18 | — | — | US | disclosed |
| WO-2013083418-A1 | PROCESS FOR THE MANUFACTURE OF 1, 1'-DIFLUOROSUBSTITUTED DIALKYL CARBONATES, ISOMERS THEREOF AND ELECTROLYTE COMPOSITIONS CONTAINING THEM | SOLVAY SA (BE) | 2013-06-13 | — | — | WO | disclosed |
| EP-2602241-A1 | Process for the manufacture of 1, 1'-difluorosubstituted dialkyl carbonates, isomers thereof and electrolyte compositions containing them | SOLVAY SA (BE) | 2013-06-12 | — | — | EP | disclosed |
| WO-2013079397-A1 | FLUORINATED DERIVATIVES OF MELDRUM'S ACID, A METHOD FOR THE PREPARATION OF THE SAME, AND THEIR USE AS A SOLVENT ADDITIVE | SOLVAY SA (BE) | 2013-06-06 | — | — | WO | disclosed |
| US-8450043-B2 | Patterning nano-scale patterns on a film comprising unzipping copolymers | INTERNATIONAL BUSINESS MACHINES CORPORATION (US) | 2013-05-28 | — | — | US | disclosed |
| US-20130072467-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2013-03-21 | — | — | US | disclosed |
| US-8343992-B2 | Synthesis of R-N-methylnaltrexone | PROGENICS PHARMACEUTICALS, INC. (US) | 2013-01-01 | — | — | US | disclosed |
| WO-2012170554-A1 | N-BIPHENYLMETHYLINDOLE MODULATORS OF PPARG | KAMENECKA THEODORE MARK (US) | 2012-12-13 | — | — | WO | disclosed |
| US-8329727-B2 | Imidazo[4,5-c]pyridine compounds and methods of antiviral treatment | GILEAD SCIENCES, INC. (US) | 2012-12-11 | — | — | US | disclosed |
| US-8329727-B2 | Imidazo[4,5-c]pyridine compounds and methods of antiviral treatment | GILEAD SCIENCES, INC. (US) | 2012-12-11 | — | — | US | disclosed |
| US-20120309757-A1 | N-BIPHENYLMETHYLINDOLE MODULATORS OF PPARG | SCRIPPS RESEARCH INSTITUTE, THE (US) | 2012-12-06 | — | — | US | disclosed |
| US-20120301672-A1 | PATTERNING NANO-SCALE PATTERNS ON A FILM COMPRISING UNZIPPING COPOLYMERS | INTERNATIONAL BUSINESS MACHINES CORPORATION (US) | 2012-11-29 | — | — | US | disclosed |
| US-20120297905-A1 | PATTERNING NANO-SCALE PATTERNS ON A FILM COMPRISING UNZIPPING COPOLYMERS | INTERNATIONAL BUSINESS MACHINES CORPORATION (US) | 2012-11-29 | — | — | US | disclosed |
| EP-2521553-A2 | METHODS AND COMPOSITIONS OF TARGETED DRUG DEVELOPMENT | Errico, Joseph P. (US) | 2012-11-14 | — | — | EP | disclosed |
| WO-2012146525-A1 | LITHIUM AIR BATTERY CELL | SOLVAY SA (BE) | 2012-11-01 | — | — | WO | disclosed |
| CN-102659620-A | Synthesis method of 2,4-bi-(trifluoromethyl) benzylhydrazine | UNIV SOUTHEAST | 2012-09-12 | — | — | CN | disclosed |
| EP-2494648-A1 | LITHIUM SULFUR BATTERY | Solvay Fluor GmbH (DE) | 2012-09-05 | — | — | EP | disclosed |
| US-20120214043-A1 | Lithium sulfur battery | SOLVAY FLUOR GMBH (DE) | 2012-08-23 | — | — | US | disclosed |
| EP-2450359-A2 | (R)-N-Methylnaltrexone | Progenics Pharmaceuticals, Inc. (US) | 2012-05-09 | — | — | EP | disclosed |
| US-20120082944-A1 | Patterning nano-scale patterns on a film comprising unzipping copolymers | INTERNATIONAL BUSINESS MACHINES CORPORATION (US) | 2012-04-05 | — | — | US | disclosed |
| EP-2412372-A1 | 2-Aminooxazole derivatives for use as TRPV1 antagonists for treating i.a. pain, inflammation, neurodegenerative diseases or gastrointestinal diseases | Abbott Laboratories (US) | 2012-02-01 | — | — | EP | disclosed |
| US-20110301193-A1 | METHODS AND COMPOSITIONS OF TARGETED DRUG DEVELOPMENT | Errico, Joseph P. (US) | 2011-12-08 | — | — | US | disclosed |
| US-20110301193-A1 | METHODS AND COMPOSITIONS OF TARGETED DRUG DEVELOPMENT | Errico, Joseph P. (US) | 2011-12-08 | — | — | US | disclosed |
| US-20110301193-A1 | METHODS AND COMPOSITIONS OF TARGETED DRUG DEVELOPMENT | Errico, Joseph P. (US) | 2011-12-08 | — | — | US | disclosed |
| US-7998993-B2 | TRPV1 antagonists | ABBOTT LABORATORIES (US) | 2011-08-16 | — | — | US | disclosed |
| WO-2011092505-A1 | S100 PROTEIN BINDING INTERACTION INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2011-08-04 | — | — | WO | disclosed |
| US-20110190344-A1 | BENZIMIDAZOLE MODULATORS OF VR1 | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-08-04 | — | — | US | disclosed |
| US-20110190364-A1 | BENZIMIDAZOLE MODULATORS OF VR1 | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-08-04 | — | — | US | disclosed |
| EP-2220059-B1 | 2-AMINOOXAZOLE DERIVATIVES AS TRPVL ANTAGONISTS USEFUL FOR TREATING PAIN | ABBOTT LAB (US) | 2011-08-03 | — | — | EP | disclosed |
| WO-2011085126-A2 | METHODS AND COMPOSITIONS OF TARGETED DRUG DEVELOPMENT | ERRICO JOSEPH P | 2011-07-14 | — | — | WO | disclosed |
| US-7951829-B2 | Benzimidazole modulators of VR1 | JANSSEN PHARMACEUTICA NV (BE) | 2011-05-31 | — | — | US | disclosed |
| WO-2011051275-A1 | LITHIUM SULFUR BATTERY | SOLVAY FLUOR GMBH (DE) | 2011-05-05 | — | — | WO | disclosed |
| EP-2284157-A1 | Quinolines useful in treating cardiovascular disease | Wyeth (US) | 2011-02-16 | — | — | EP | disclosed |
| US-20100311781-A1 | SYNTHESIS OF R-N-METHYLNALTREXONE | PROGENICS PHARMACEUTICALS, INC. | 2010-12-09 | — | — | US | disclosed |
| EP-2021330-B1 | BENZIMIDAZOLE MODULATORS OF VR1 | JANSSEN PHARMACEUTICA NV (BE) | 2010-09-22 | — | — | EP | disclosed |
| EP-2220059-A1 | 2-AMINOOXAZOLE DERIVATIVES AS TRPVL ANTAGONISTS USEFUL FOR TREATING PAIN | Abbott Laboratories (US) | 2010-08-25 | — | — | EP | disclosed |
| EP-1399445-B9 | SUBSTITUTED PYRROLOQUINOLINES AND PYRIDOQUINOLINES AS SEROTONIN AGONISTS AND ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2010-07-21 | — | — | EP | disclosed |
| US-7749992-B2 | Compounds and methods for treating dislipidemia | ELI LILLY AND COMPANY (US) | 2010-07-06 | — | — | US | disclosed |
| EP-1476435-B1 | NOVEL PYRIDIN- AND PYRIMIDIN-DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2010-06-30 | — | — | EP | disclosed |
| US-7674904-B2 | Synthesis of R-N-methylnaltrexone | PROGENICS PHARMACEUTICALS, INC. (US) | 2010-03-09 | — | — | US | disclosed |
| US-20100028301-A1 | IMIDAZO[4,5-c]PYRIDINE COMPOUNDS AND METHODS OF ANTIVIRAL TREATMENT | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2010-02-04 | — | — | US | disclosed |
| US-20100028301-A1 | IMIDAZO[4,5-c]PYRIDINE COMPOUNDS AND METHODS OF ANTIVIRAL TREATMENT | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2010-02-04 | — | — | US | disclosed |
| US-7648998-B2 | 5-((3-(4-chlorophenyl)isoxazol-5-yl)methyl)-2-(2-fluorophenyl)-5H-imidazo[4,5-c]pyridine; hepatitis-C-virus | K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2010-01-19 | — | — | US | disclosed |
| US-7648998-B2 | 5-((3-(4-chlorophenyl)isoxazol-5-yl)methyl)-2-(2-fluorophenyl)-5H-imidazo[4,5-c]pyridine; hepatitis-C-virus | K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2010-01-19 | — | — | US | disclosed |
| US-20090324581-A1 | HETEROARYLAMIDE LOWER CARBOXYLIC ACID DERIVATIVE | DAIICHI SANKYO COMPANY LIMITED (JP) | 2009-12-31 | — | — | US | disclosed |
| US-20090324581-A1 | HETEROARYLAMIDE LOWER CARBOXYLIC ACID DERIVATIVE | DAIICHI SANKYO COMPANY LIMITED (JP) | 2009-12-31 | — | — | US | disclosed |
| US-20090324581-A1 | HETEROARYLAMIDE LOWER CARBOXYLIC ACID DERIVATIVE | DAIICHI SANKYO COMPANY LIMITED (JP) | 2009-12-31 | — | — | US | disclosed |
| EP-1670768-B1 | COMPOUNDS AND METHODS FOR TREATING DYSLIPIDEMIA | LILLY CO ELI (US) | 2009-09-09 | — | — | EP | disclosed |
| EP-2098512-A1 | Compounds and methods for treating dyslipidemia | Eli Lilly & Company (US) | 2009-09-09 | — | — | EP | disclosed |
| US-7576215-B2 | Quinolines and pharmaceutical compositions thereof | WYETH (US) | 2009-08-18 | — | — | US | disclosed |
| US-20090197167-A1 | Fluorinated Additives For Lithium Ion Batteries | SOLVAY FLUOR GMBH (DE) | 2009-08-06 | — | — | US | disclosed |
| EP-1399445-B1 | SUBSTITUTED PYRROLOQUINOLINES AND PYRIDOQUINOLINES AS SEROTONIN AGONISTS AND ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2009-08-05 | — | — | EP | disclosed |
| US-20090124666-A1 | TRPV1 ANTAGONISTS | ABBOTT LABORATORIES (US) | 2009-05-14 | — | — | US | disclosed |
| WO-2009055749-A1 | 2-AMINOOXAZOLE DERIVATIVES AS TRPVL ANTAGONISTS USEFUL FOR TREATING PAIN | ABBOTT LABORATORIES (US) | 2009-04-30 | — | — | WO | disclosed |
| US-20090093464-A1 | Naphthalene Derivatives as Modulators of the Glucocorticoid Receptor | SMITHKLINE BEECHMA CORPORATION (US) | 2009-04-09 | — | — | US | disclosed |
| EP-1453810-B1 | SUBSTITUTED 4-PHENYLTETRAHYDROISOQUINOLINES, METHOD FOR THE PRODUCTION THEREOF, THE USE THEREOF AS MEDICAMENTS, IN ADDITION TO A MEDICAMENT CONTAINING SAME | SANOFI AVENTIS DEUTSCHLAND (DE) | 2009-03-18 | — | — | EP | disclosed |
| EP-2021330-A2 | BENZIMIDAZOLE MODULATORS OF VR1 | Janssen Pharmaceutica, N.V. (BE) | 2009-02-11 | — | — | EP | disclosed |
| EP-2017263-A1 | HETEROARYLAMIDE LOWER CARBOXYLIC ACID DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2009-01-21 | — | — | EP | disclosed |
| EP-2017263-A1 | HETEROARYLAMIDE LOWER CARBOXYLIC ACID DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2009-01-21 | — | — | EP | disclosed |
| EP-1996198-A1 | ALKYLAMINE-SUBSTITUTED BICYCLIC ARYL COMPOUNDS USEFUL AS MODULATORS OF PPAR | Kalypsys, Inc. (US) | 2008-12-03 | — | — | EP | disclosed |
| US-20080255202-A1 | Phenylthioacetic Acid Derivatives and Use Thereof | BAYER HEALTHCARE AG (DE) | 2008-10-16 | — | — | US | disclosed |
| EP-1938404-A1 | FLUORINATED ADDITIVES FOR LITHIUM ION BATTERIES | Solvay Fluor GmbH (DE) | 2008-07-02 | — | — | EP | disclosed |
| EP-1913001-A2 | (R)-N-METHYLNALTREXONE, PROCESSES FOR ITS SYNTHESIS AND ITS PHARMACEUTICAL USE | PROGENICS PHARMACEUTICALS, INC. (US) | 2008-04-23 | — | — | EP | disclosed |
| EP-1567498-B1 | MANDELIC ACID DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2008-01-23 | — | — | EP | disclosed |
| WO-2007130780-A2 | BENZIMIDAZOLE MODULATORS OF VR1 | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-11-15 | — | — | WO | disclosed |
| US-20070259936-A1 | Benzimidazole Modulators of VR1 | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-11-08 | — | — | US | disclosed |
| EP-1851204-A1 | NAPHTHALENE DERIVATIVES AS MODULATORS OF THE GLUCOCORTICOID RECEPTOR | SmithKline Beecham Corporation (US) | 2007-11-07 | — | — | EP | disclosed |
| US-20070254869-A1 | Compounds And Methods For Treating Dislipidemia | ELI LILLY AND COMPANY (US) | 2007-11-01 | — | — | US | disclosed |
| US-20070244148-A1 | Imidazo 4,5-C Pyridine Compounds and Methods of Antiviral Treatment | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2007-10-18 | — | — | US | disclosed |
| US-20070244148-A1 | Imidazo 4,5-C Pyridine Compounds and Methods of Antiviral Treatment | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2007-10-18 | — | — | US | disclosed |
| WO-2007109577-A1 | ALKYLAMINE-SUBSTITUTED BICYCLIC ARYL COMPOUNDS USEFUL AS MODULATORS OF PPAR | KALYPSYS, INC. (US) | 2007-09-27 | — | — | WO | disclosed |
| US-20070219193-A1 | ALKYLAMINE-SUBSTITUTED BICYCLIC ARYL COMPOUNDS USEFUL AS MODULATORS OF PPAR | KALYPSYS, INC (US) | 2007-09-20 | — | — | US | disclosed |
| US-20070208026-A1 | N-Containing Heteroaromatic Compounds As Modulators Of Ppars And Methods Of Treating Metabolic Disorders | KALYPSYS, INC. | 2007-09-06 | — | — | US | disclosed |
| US-7256219-B2 | Multifluoro-substituted chalcones and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. (US) | 2007-08-14 | — | — | US | disclosed |
| US-20070099946-A1 | Synthesis of R-N-methylnaltrexone | PROGENICS PHARMACEUTICALS, INC | 2007-05-03 | — | — | US | disclosed |
| WO-2007042471-A1 | FLUORINATED ADDITIVES FOR LITHIUM ION BATTERIES | SOLVAY FLUOR GMBH (DE) | 2007-04-19 | — | — | WO | disclosed |
| WO-2006127899-A2 | (R)-N-METHYLNALTREXONE, PROCESSES FOR ITS SYNTHESIS AND ITS PHARMACEUTICAL USE | PROGENICS PHARMACEUTICALS, INC. (US) | 2006-11-30 | — | — | WO | disclosed |
| US-7129238-B2 | Mandelic acid derivatives | HOFFMANN-LA ROCHE INC. (US) | 2006-10-31 | — | — | US | disclosed |
| US-7115566-B2 | Compounds and method for the prevention and treatment of diabetic retinopathy | UNIVERSITY OF FLORIDA (US) | 2006-10-03 | — | — | US | disclosed |
| EP-1613326-B1 | (3-{3-'(2,4-BIS-TRIFLUORMETHYL-BENZYL)-(5-ETHYL-PYRIMIDIN-2-YL)-AMINO]-PROPOXY}-PHENYL)-ACETIC ACID AND RELATED COMPOUNDS AS MODULATORS OF PPARS AND METHODS OF TREATING METABOLIC DISORDERS | KALYPSYS INC (US) | 2006-09-13 | — | — | EP | disclosed |
| WO-2006091592-A1 | NAPHTHALENE DERIVATIVES AS MODULATORS OF THE GLUCOCORTICOID RECEPTOR | SMITHKLINE BEECHAM CORPORATION (US) | 2006-08-31 | — | — | WO | disclosed |
| EP-1692111-A2 | QUINOLINES USEFUL IN TREATING CARDIOVASCULAR DISEASE | Wyeth, A Corporation of the State of Delaware (US) | 2006-08-23 | — | — | EP | disclosed |
| EP-1687641-A2 | TREATING NEUROPATHIC PAIN WITH NEUROPEPTIDE FF RECEPTOR 2 AGONISTS | Acadia Pharmaceuticals Inc. (US) | 2006-08-09 | — | — | EP | disclosed |
| US-20060079554-A1 | Inhibitors of monomine uptake | ELI LILLY AND COMPANY | 2006-04-13 | — | — | US | disclosed |
| US-7022718-B2 | Pyridine and pyrimidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2006-04-04 | — | — | US | disclosed |
| EP-1613326-A1 | (3-{3-´(2,4-BIS-TRIFLUORMETHYL-BENZYL)-(5-ETHYL-PYRIMIDIN-2-YL)-AMINO!-PROPOXY}-PHENYL)-ACETIC ACID AND RELATED COMPOUNDS AS MODULATORS OF PPARS AND METHODS OF TREATING METABOLIC DISORDERS | Kalypsys, Inc. (US) | 2006-01-11 | — | — | EP | disclosed |
| US-6967197-B2 | Thiazepinyl hydroxamic acid derivatives as matrix metalloproteinase inhibitors | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-11-22 | — | — | US | disclosed |
| US-6943145-B2 | Compounds and method for the prevention and treatment of diabetic retinopathy | UNIVERSITY OF FLORIDA (US) | 2005-09-13 | — | — | US | disclosed |
| EP-1569905-A2 | INHIBITORS OF MONOAMINE UPTAKE | ELI LILLY AND COMPANY (US) | 2005-09-07 | — | — | EP | disclosed |
| EP-1567498-A2 | MANDELIC ACID DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-08-31 | — | — | EP | disclosed |
| EP-1551841-A1 | PYRAZOLOPYRIMIDINES AS KINASE INHIBITORS | SmithKline Beecham Corporation (US) | 2005-07-13 | — | — | EP | disclosed |
| WO-2005058834-A2 | QUINOLINES USEFUL IN TREATING CARDIOVASCULAR DISEASE | WYETH (US) | 2005-06-30 | — | — | WO | disclosed |
| US-20050143405-A1 | Pyridine and pyrimidine derivatives | BOEHRINGER MARKUS (CH) | 2005-06-30 | — | — | US | disclosed |
| US-20050136444-A1 | Treating neuropathic pain with neuropeptide FF receptor 2 agonists | ACADIA PHARMACEUTICALS INC. | 2005-06-23 | — | — | US | disclosed |
| US-20050131014-A1 | Quinolines useful in treating cardiovascular disease | WYETH (US) | 2005-06-16 | — | — | US | disclosed |
| WO-2005031000-A2 | TREATING NEUROPATHIC PAIN WITH NEUROPEPTIDE FF RECEPTOR 2 AGONISTS | ACADIA PHARMACEUTICALS INC. (US) | 2005-04-07 | — | — | WO | disclosed |
| US-20050070532-A1 | Aryl compounds as modulators of PPARS and methods of treating metabolic disorders | KALYPSYS, INC. | 2005-03-31 | — | — | US | disclosed |
| US-6867205-B2 | Pyridine and pyrimidine derivatives | HOFFMAN-LA ROCHE INC. (US) | 2005-03-15 | — | — | US | disclosed |
| US-6849619-B2 | Substituted pyridoindoles as serotonin agonists and antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-02-01 | — | — | US | disclosed |
| EP-1476435-A1 | NOVEL PYRIDIN- AND PYRIMIDIN-DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2004-11-17 | — | — | EP | disclosed |
| WO-2004093879-A1 | (3-{3-‘(2,4-BIS-TRIFLUORMETHYL-BENZYL)-(5-ETHYL-PYRIMIDIN-2-YL)-AMINO!-PROPOXY}-PHENYL)-ACETIC ACID AND RELATED COMPOUNDS AS MODULATORS OF PPARS AND METHODS OF TREATING METABOLIC DISORDERS | KALYPSYS, INC. (US) | 2004-11-04 | — | — | WO | disclosed |
| WO-2004092130-A2 | N-CONTAINING HETEROAROMATIC COMPOUNDS AS MODULATORS OF PPARS AND METHODS OF TREATING METABOLIC DISORDERS | KALYPSYS, INC. (US) | 2004-10-28 | — | — | WO | disclosed |
| WO-2003068757-A9 | NOVEL PYRIDIN- AND PYRIMIDIN-DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2004-10-07 | — | — | WO | disclosed |
| US-20040186094-A1 | Substituted pyridoindoles as serotonin agonists and antagonists | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-09-23 | — | — | US | disclosed |
| US-20040171637-A1 | Multifluoro-substituted chalcones and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. | 2004-09-02 | — | — | US | disclosed |
| US-6777406-B2 | SUCH AS PYRIDO(3,2,1-IJ)PYRROLO(3,4-C)QUINOLIN-8-ONE DERI-VATIVES; CENTRAL NERVOUS SYSTEM DISORDERS; GASTROINTESTINAL DISORDERS | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-08-17 | — | — | US | disclosed |
| WO-2004052858-A2 | INHIBITORS OF MONOAMINE UPTAKE | ELI LILLY AND COMPANY (US) | 2004-06-24 | — | — | WO | disclosed |
| US-20040122057-A1 | Novel mandelic acid derivatives | HOFFMANN-LA ROCHE INC. | 2004-06-24 | — | — | US | disclosed |
| WO-2004048335-A2 | MANDELIC ACID DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2004-06-10 | — | — | WO | disclosed |
| US-20040092502-A1 | SUBSTITUTED PYRROLOQUINOLINES AND PYRIDOQUINOLINES AS SEROTONIN AGONISTS AND ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY, (FORMERLY D/B/A DUPONT PHARMACEUTICALS COMPANY) | 2004-05-13 | — | — | US | disclosed |
| US-20040082501-A1 | Compounds and method for the prevention and treatment of diabetic retinopathy | FLORIDA, UNIVERSITY OF | 2004-04-29 | — | — | US | disclosed |
| US-6699852-B2 | ANTISEROTONIN AGENTS; CENTRAL NERVOUS SYSTEM DISORDERS; ANTIDEPRESSANTS | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-03-02 | — | — | US | disclosed |
| EP-1390336-A1 | METHOD FOR PRODUCING AROMATIC ALDEHYDES AND KETONES BY THE CATALYTIC OXIDATION OF ALKYL-AROMATIC COMPOUNDS | DSM Fine Chemicals Austria Nfg GmbH & Co KG (AT) | 2004-02-25 | — | — | EP | disclosed |
| WO-2004009602-A1 | PYRAZOLOPYRIMIDINES AS KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-01-29 | — | — | WO | disclosed |
| US-20030216382-A1 | Pyridine and pyrimidine derivatives | HOFFMAN-LA ROCHE INC. | 2003-11-20 | — | — | US | disclosed |
| US-20030211981-A1 | Compounds and method for the prevention and treatment of diabetic retinopathy | BODOR NICHOLAS STEPHEN (US) | 2003-11-13 | — | — | US | disclosed |
| WO-2003068757-A1 | NOVEL PYRIDIN- AND PYRIMIDIN-DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-08-21 | — | — | WO | disclosed |
| US-20030134849-A1 | Thiazepinyl hydroxamic acid derivatives as matrix metalloproteinase inhibitors | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-07-17 | — | — | US | disclosed |
| WO-2003033505-A1 | METHOD FOR ORGANOMETALLIC PRODUCTION OF ORGANIC INTERMEDIATE PRODUCTS VIA LITHIUM AMIDE BASES | CLARIANT GMBH (DE) | 2003-04-24 | — | — | WO | disclosed |
| WO-2002096849-A1 | METHOD FOR PRODUCING AROMATIC ALDEHYDES AND KETONES BY THE CATALYTIC OXIDATION OF ALKYL-AROMATIC COMPOUNDS | DSM FINE CHEMICALS AUSTRIA NFG GMBH & CO KG (AT) | 2002-12-05 | — | — | WO | disclosed |
| US-20020173503-A1 | Substituted pyridoindoles as serotonin agonists and antagonists | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-11-21 | — | — | US | disclosed |
| WO-2002072544-A2 | MULTIFLUORO-SUBSTITUTED CHALCONES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | CYTOVIA, INC. (US) | 2002-09-19 | — | — | WO | disclosed |
| US-6440933-B1 | PEPTIDE DERIVATIVES WHICH ARE DIHYDROPYRIDINE-PYRIDINIUM SALT-TYPE REDOX TARGETOR MOIETY, A BULKY LIPOPHILIC FUNCTION AND AN AMINO ACID/DIPEPTIDE/TRIPEPTIDE SPACER; GROWTH FACTOR INHIBITOR, ESPECIALLY SOMATOSTATIN ANALOGS, RETINA | UNIVERSITY OF FLORIDA | 2002-08-27 | — | — | US | disclosed |
| US-6376712-B2 | REDUCTION OF THE CORRESPONDING OXIME COMPOUND | CENTRAL GLASS COMPANY, LIMITED (JP) | 2002-04-23 | — | — | US | disclosed |
| US-20020042541-A1 | Process for producing bis( trifluoromethyl)benzaldehyde | CENTRAL GLASS COMPANY, LIMITED (JP) | 2002-04-11 | — | — | US | disclosed |
| US-20020013500-A1 | Process for producing trifluoromethylbenzylamines | CENTRAL GLASS COMPANY, LIMITED (JP) | 2002-01-31 | — | — | US | disclosed |
| US-6331649-B1 | REDUCING AN OXIME BY CATALYTIC HYDROGENTATION IN SOLVENT CONTAINING AN ACID | CENTRAL GLASS COMPANY, LIMITED (JP) | 2001-12-18 | — | — | US | disclosed |
| EP-0661986-B1 | BRAIN-ENHANCED DELIVERY OF NEUROACTIVE PEPTIDES BY SEQUENTIAL METABOLISM | UNIV FLORIDA (US) | 1999-06-09 | — | — | EP | disclosed |
| US-5639885-A | Redox amino acids and peptides containing them | UNIVERSITY OF FLORIDA (US) | 1997-06-17 | — | — | US | disclosed |
| US-5624894-A | Brain-enhanced delivery of neuroactive peptides by sequential metabolism | UNIVERSITY OF FLORIDA (US) | 1997-04-29 | — | — | US | disclosed |
| EP-0661986-A4 | BRAIN-ENHANCED DELIVERY OF NEUROACTIVE PEPTIDES BY SEQUENTIAL METABOLISM. | UNIV FLORIDA (US) | 1997-04-23 | — | — | EP | disclosed |
| US-5618803-A | TO BRAIN | UNIVERSITY OF FLORIDA (US) | 1997-04-08 | — | — | US | disclosed |
| EP-0539493-B1 | TARGETED DRUG DELIVERY VIA PHOSPHONATE DERIVATIVES | BODOR NICHOLAS S (US) | 1997-03-26 | — | — | EP | disclosed |
| US-5525727-A | ANALGESIC OR NARCOTIC ANTAGONIST | UNIVERSITY OF FLORIDA (US) | 1996-06-11 | — | — | US | disclosed |
| EP-0577725-A4 | TARGETED DRUG DELIVERY VIA MIXED PHOSPHATE DERIVATIVES | UNIV FLORIDA (US) | 1996-04-17 | — | — | EP | disclosed |
| US-5502073-A | INSECTICIDES OR ANTHELMINTICS | THE WELLCOME FOUNDATION (GB) | 1996-03-26 | — | — | US | disclosed |
| EP-0110955-B1 | BRAIN-SPECIFIC DRUG DELIVERY | UNIV FLORIDA (US) | 1995-08-23 | — | — | EP | disclosed |
| EP-0661986-A1 | BRAIN-ENHANCED DELIVERY OF NEUROACTIVE PEPTIDES BY SEQUENTIAL METABOLISM | UNIVERSITY OF FLORIDA (US) | 1995-07-12 | — | — | EP | disclosed |
| US-5413996-A | Delivery of steroid sex hormone or antiinflammatory steroid to the brain | UNIVERSITY OF FLORIDA (US) | 1995-05-09 | — | — | US | disclosed |
| EP-0442340-B1 | Process for the preparation of an organolithium compound starting from 1,3-bis(trifluoromethyl)-benzene | HOFFMANN LA ROCHE (CH) | 1995-02-22 | — | — | EP | disclosed |
| US-5389623-A | Redox carriers for brain-specific drug delivery | UNIVERSITY OF FLORIDA (US) | 1995-02-14 | — | — | US | disclosed |
| WO-1994006450-A1 | BRAIN-ENHANCED DELIVERY OF NEUROACTIVE PEPTIDES BY SEQUENTIAL METABOLISM | UNIVERSTIY OF FLORIDA (US) | 1994-03-31 | — | — | WO | disclosed |
| US-5296483-A | Antidepressant | UNIVERSITY OF FLORIDA (US) | 1994-03-22 | — | — | US | disclosed |
| EP-0577725-A1 | TARGETED DRUG DELIVERY VIA MIXED PHOSPHATE DERIVATIVES | UNIVERSITY OF FLORIDA (US) | 1994-01-12 | — | — | EP | disclosed |
| EP-0293071-B1 | REDOX AMINO ACIDS AND PEPTIDES CONTAINING THEM | UNIVERSITY OF FLORIDA (US) | 1993-09-01 | — | — | EP | disclosed |
| EP-0539493-A4 | TARGETED DRUG DELIVERY VIA PHOSPHONATE DERIVATIVES | — | 1993-06-02 | — | — | EP | disclosed |
| EP-0539493-A1 | TARGETED DRUG DELIVERY VIA PHOSPHONATE DERIVATIVES. | BODOR NICHOLAS S (US) | 1993-05-05 | — | — | EP | disclosed |
| US-5187158-A | Sustained delivery of viricides | UNIVERSITY OF FLORIDA (US) | 1993-02-16 | — | — | US | disclosed |
| US-5177064-A | TARGETED DRUG DELIVERY VIA PHOSPHONATE DERIVATIVES | UNIVERSITY OF FLORIDA (US) | 1993-01-05 | — | — | US | disclosed |
| EP-0294229-B1 | NOVEL HETEROCYCLIC PESTICIDAL COMPOUNDS | THE WELLCOME FOUNDATION LIMITED (GB) | 1992-12-02 | — | — | EP | disclosed |
| US-5162577-A | Chemical intermediates | HOFFMANN-LA ROCHE INC. (US) | 1992-11-10 | — | — | US | disclosed |
| WO-1992017185-A1 | TARGETED DRUG DELIVERY VIA MIXED PHOSPHATE DERIVATIVES | UNIVERSITY OF FLORIDA (US) | 1992-10-15 | — | — | WO | disclosed |
| US-5087618-A | Antiviral, anticancer, antitumor agents | UNIVERSITY OF FLORIDA (US) | 1992-02-11 | — | — | US | disclosed |
| WO-1992000988-A1 | TARGETED DRUG DELIVERY VIA PHOSPHONATE DERIVATIVES | BODOR NICHOLAS S (US) | 1992-01-23 | — | — | WO | disclosed |
| US-5082853-A | Drug delivery | BODOR NICHOLAS S (US) | 1992-01-21 | — | — | US | disclosed |
| US-5079366-A | To derivatize pharmaceutical peptides for transport across the blood/brain barrier | UNIVERSITY OF FLORIDA (US) | 1992-01-07 | — | — | US | disclosed |
| EP-0442340-A2 | Process for the preparation of an organolithium compound starting from 1,3-bis(trifluoromethyl)-benzene | F. HOFFMANN-LA ROCHE AG (CH) | 1991-08-21 | — | — | EP | disclosed |
| US-5008257-A | Penicillin or cephalosporin antibiotics | UNIVERSITY OF FLORIDA (US) | 1991-04-16 | — | — | US | disclosed |
| US-4933438-A | Brain-specific analogues of centrally acting amines | UNIVERSITY OF FLORIDA (US) | 1990-06-12 | — | — | US | disclosed |
| US-4900837-A | Brain-specific drug delivery of steroid sex hormones cleaved from pyridinium carboxylates and dihydro-pyridine carboxylate precursors | UNIVERSITY OF FLORIDA (US) | 1990-02-13 | — | — | US | disclosed |
| EP-0174342-B1 | BRAIN-SPECIFIC ANALOGUES OF CENTRALLY ACTING AMINES | UNIVERSITY OF FLORIDA (US) | 1989-12-20 | — | — | EP | disclosed |
| US-4888427-A | DIHYDROPYRIDINE-PYRIDINIUM SALT REDOX SYSTEM | UNIVERSITY OF FLORIDA (US) | 1989-12-19 | — | — | US | disclosed |
| US-4880816-A | Brain-specific delivery of dopamine utilizing dihydropyridine/pyridinium salt-type redox carriers | UNIVERSITY OF FLORIDA (US) | 1989-11-14 | — | — | US | disclosed |
| US-4880921-A | Brain-specific drug delivery | UNIVERSITY OF FLORIDA (US) | 1989-11-14 | — | — | US | disclosed |
| US-4829070-A | PRODRUG FOR SUSTAINED RELEASE OF DOPAMINE | UNIVERSITY OF FLORIDA (US) | 1989-05-09 | — | — | US | disclosed |
| US-4824850-A | DIHYDROPYRIDINE-PYRIDINIUM SALT REDOX CARRIER | UNIVERSITY OF FLORIDA (US) | 1989-04-25 | — | — | US | disclosed |
| EP-0294229-A2 | Novel heterocyclic pesticidal compounds | THE WELLCOME FOUNDATION LIMITED (GB) | 1988-12-07 | — | — | EP | disclosed |
| EP-0293071-A1 | Redox amino acids and peptides containing them | UNIVERSITY OF FLORIDA (US) | 1988-11-30 | — | — | EP | disclosed |
| US-4771059-A | CENTRAL NERVOUS SYSTEM | UNIVERSITY OF FLORIDA (US) | 1988-09-13 | — | — | US | disclosed |
| EP-0262696-A2 | Brain-specific drug delivery | UNIVERSITY OF FLORIDA (US) | 1988-04-06 | — | — | EP | disclosed |
| EP-0256577-A2 | Brain-specific drug delivery | UNIVERSITY OF FLORIDA (US) | 1988-02-24 | — | — | EP | disclosed |
| US-4727079-A | Brain-specific dopaminergic activity involving dihydropyridine carboxamides, dihydroquinoline and isoquinoline carboxamides | UNIVERSITY OF FLORIDA (US) | 1988-02-23 | — | — | US | disclosed |
| EP-0224283-A2 | Brain-specific drug delivery | UNIVERSITY OF FLORIDA (US) | 1987-06-03 | — | — | EP | disclosed |
| EP-0222425-A2 | Brain-specific drug delivery | UNIVERSITY OF FLORIDA (US) | 1987-05-20 | — | — | EP | disclosed |
| EP-0221588-A2 | Brain-specific drug delivery | UNIVERSITY OF FLORIDA (US) | 1987-05-13 | — | — | EP | disclosed |
| EP-0218300-A2 | Brain-specific drug delivery | UNIVERSITY OF FLORIDA (US) | 1987-04-15 | — | — | EP | disclosed |
| EP-0036426-B1 | NOVEL PROCESS AND INTERMEDIATES USEFUL IN THE PREPARATION OF SYMPATHOMIMETIC AMINES | INTERx RESEARCH CORPORATION (US) | 1986-04-23 | — | — | EP | disclosed |
| EP-0174342-A1 | BRAIN-SPECIFIC ANALOGUES OF CENTRALLY ACTING AMINES. | UNIV FLORIDA (US) | 1986-03-19 | — | — | EP | disclosed |
| WO-1985003937-A1 | BRAIN-SPECIFIC ANALOGUES OF CENTRALLY ACTING AMINES | UNIVERSITY OF FLORIDA (US) | 1985-09-12 | — | — | WO | disclosed |
| US-4540564-A | DIHYDROPYRIDINE AND/OR PYRIDINIUM SALT REDOX CARRIER | UNIVERSITY OF FLORIDA (US) | 1985-09-10 | — | — | US | disclosed |
| EP-0110955-A1 | BRAIN-SPECIFIC DRUG DELIVERY. | UNIV FLORIDA (US) | 1984-06-20 | — | — | EP | disclosed |
| WO-1983003968-A1 | BRAIN-SPECIFIC DRUG DELIVERY | UNIVERSITY OF FLORIDA (US) | 1983-11-24 | — | — | WO | disclosed |
| US-4338455-A | Novel process and intermediates useful in the preparation of sympathomimetic amines | MERCK & CO., INC. (US) | 1982-07-06 | — | — | US | disclosed |
| US-4336400-A | BRONCHODILATOR AGENTS, CARDIOVASCULAR STIMULANTS | STERLING DRUG INC. (US) | 1982-06-22 | — | — | US | disclosed |
| US-4285947-A | DIURETICS, HYPOTENSIVES | INTERX RESEARCH CORPORATION (US) | 1981-08-25 | — | — | US | disclosed |
| EP-0032725-A1 | Novel aldehyde adducts of triamterene and a pharmaceutical composition containing the same | MERCK & CO. INC. (US) | 1981-07-29 | — | — | EP | disclosed |
| US-4275219-A | Novel process and intermediates useful in the preparation of sympathomimetic amines | INTERX RESEARCH CORPORATION (US) | 1981-06-23 | — | — | US | disclosed |
| US-RE30241-E | BRONCHODILATION, ADRENERGIC STIMULANTS | STERLING DRUG INC. (US) | 1980-03-25 | — | — | US | disclosed |
| US-4145441-A | SYMPATHOMIMETIC AMINES EXHIBITING ANTI-HEMORRHOIDAL ACTIVITY | INTERX RESEARCH CORPORATION (US) | 1979-03-20 | — | — | US | disclosed |
| US-4138581-A | BRONCHODILATOR AGENTS, ADRENERGIC STIMULANTS | STERLING DRUGS INC. (US) | 1979-02-06 | — | — | US | disclosed |
| US-4094983-A | \"KETO\" SYMPATHOMIMETIC AMINES | INTERX RESEARCH CORPORATION (US) | 1978-06-13 | — | — | US | disclosed |
| US-4035405-A | Novel synthesis for preparing the hydrochloride salt of selected catecholamine derivatives | INTERX RESEARCH CORPORATION (US) | 1977-07-12 | — | — | US | disclosed |
| US-3946028-A | HYPOTENSIVE AGENTS, CORONARY VESSEL DILATORS | BAYER AKTIENGESELLSCHAFT (DT) | 1976-03-23 | — | — | US | disclosed |
| US-3946027-A | HYPOTENSIVE AGENTS, CORONARY VESSEL DILATORS | BAYER AKTIENGESELLSCHAFT (DT) | 1976-03-23 | — | — | US | disclosed |
| US-3943140-A | HYPOTENSIVE, VASODILATION | BAYER AKTIENGESELLSCHAFT (DT) | 1976-03-09 | — | — | US | disclosed |
| US-3943140-A | HYPOTENSIVE, VASODILATION | BAYER AKTIENGESELLSCHAFT (DT) | 1976-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (50 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160317547-A1 | Male Contraceptive Compositions And Methods Of Use | SHBG, CYP19A1, CYP17A1 | CES2 21/4885HCAR1 1407/4885ERN1 3949/4885 |
| US-20110190364-A1 | BENZIMIDAZOLE MODULATORS OF VR1 | VRK1, VRK2, VIL1 | CES2 2350/4885HCAR1 469/4885ERN1 2025/4885 |
| US-11608336-B2 | Prodrugs of fused-bicyclic C5aR antagonists | C5AR2, C5AR1, C3AR1 | CES2 2296/4885HCAR1 27/4885ERN1 3801/4885 |
| US-20240124434-A1 | ATF6 INHIBITORS AND USES THEREOF | ATF4, XBP1, ATF1 | CES2 2791/4885HCAR1 3887/4885ERN1 13/4885 |
| US-20250388585-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT1, PRMT5, PRMT6 | CES2 3521/4885HCAR1 3315/4885ERN1 1112/4885 |
| US-10626095-B2 | Cyanotriazole compounds | CS, PC, ACAT1 | CES2 314/4885HCAR1 340/4885ERN1 1852/4885 |
| US-20130323286-A1 | SYNTHESIS OF R-N-METHYLNALTREXONE | OPRM1, OPRK1, OPRL1 | CES2 1437/4885HCAR1 543/4885ERN1 2163/4885 |
| US-20020173503-A1 | Substituted pyridoindoles as serotonin agonists and antagonists | HTR1A, HTR1B, HTR7 | CES2 1940/4885HCAR1 663/4885ERN1 4009/4885 |
| US-12268675-B2 | Diaryl substituted 6,5-fused ring compounds as C5aR inhibitors | C5AR1, C5AR2, C3AR1 | CES2 4257/4885HCAR1 82/4885ERN1 3863/4885 |
| US-12325702-B2 | ATF6 inhibitors and uses thereof | ATF4, XBP1, ATF1 | CES2 2791/4885HCAR1 3887/4885ERN1 13/4885 |
| US-20110301193-A1 | METHODS AND COMPOSITIONS OF TARGETED DRUG DEVELOPMENT | EGFR, ERBB2, ERBB3 | CES2 3153/4885HCAR1 2090/4885ERN1 1102/4885 |
| US-20030216382-A1 | Pyridine and pyrimidine derivatives | DPP4, GPR119, G6PC1 | CES2 2336/4885HCAR1 1896/4885ERN1 507/4885 |
| US-20250136594-A1 | COMPOUNDS AND METHODS OF USE | CNKSR1, UGT1A1, REV1 | CES2 1111/4885HCAR1 222/4885ERN1 2178/4885 |
| US-20040186094-A1 | Substituted pyridoindoles as serotonin agonists and antagonists | HTR1A, HTR1B, HTR7 | CES2 1940/4885HCAR1 663/4885ERN1 4009/4885 |
| US-20190023682-A1 | INHIBITORS OF BACTERIAL RNA POLYMERASE: ARYLPROPANOYL, ARYLPROPENOYL, AND ARYLCYCLOPROPANECARBOXYL PHLOROGLUCINOLS | RNGTT, ELL, PGLS | CES2 1349/4885HCAR1 1786/4885ERN1 812/4885 |
| US-20190192491-A1 | DIARYL SUBSTITUTED 6,5-FUSED RING COMPOUNDS AS C5aR INHIBITORS | C5AR1, C5AR2, C3AR1 | CES2 4257/4885HCAR1 82/4885ERN1 3863/4885 |
| US-20240376110-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT9 | CES2 4100/4885HCAR1 3964/4885ERN1 1469/4885 |
| US-10813939-B2 | Bromodomain inhibitor as adjuvant in cancer immunotherapy | BRDT, BRD4, BRD1 | CES2 3748/4885HCAR1 2266/4885ERN1 3348/4885 |
| US-10407441-B2 | Compositions and methods for treating neoplasia, inflammatory disease and other disorders | BRPF3, EP300, BRD3 | CES2 3896/4885HCAR1 3112/4885ERN1 1853/4885 |
| US-20050070532-A1 | Aryl compounds as modulators of PPARS and methods of treating metabolic disorders | PPARG, PPARA, PPARD | CES2 373/4885HCAR1 317/4885ERN1 3214/4885 |
| US-20140163069-A1 | COMPOSITIONS OF TARGETED DRUG DEVELOPMENT | EGFR, ERBB2, ERBB3 | CES2 3856/4885HCAR1 2580/4885ERN1 1133/4885 |
| US-11479553-B2 | 5-5 fused rings as C5a inhibitors | C5AR1, C5AR2, C3AR1 | CES2 4619/4885HCAR1 152/4885ERN1 3906/4885 |
| US-20040122057-A1 | Novel mandelic acid derivatives | F7, F11, F9 | CES2 3770/4885HCAR1 202/4885ERN1 1226/4885 |
| US-20070099946-A1 | Synthesis of R-N-methylnaltrexone | OPRM1, OPRK1, OPRL1 | CES2 1437/4885HCAR1 543/4885ERN1 2163/4885 |
| US-20170035730-A1 | PPARG MODULATORS FOR TREATMENT OF OSTEOPOROSIS | PPARG, PPARA, PPARD | CES2 4834/4885HCAR1 466/4885ERN1 1891/4885 |
| US-20130210813-A1 | Male Contraceptive Compositions and Methods of Use | SHBG, CYP19A1, CYP17A1 | CES2 21/4885HCAR1 1407/4885ERN1 3949/4885 |
| US-20140322618-A1 | FLUORINATED DERIVATIVES OF MELDRUM'S ACID, A METHOD FOR THE PREPARATION OF THE SAME, AND THEIR USE AS A SOLVENT ADDITIVE | FXR2, FXR1, SLC10A1 | CES2 2938/4885HCAR1 2820/4885ERN1 2971/4885 |
| US-20190300526-A1 | PRODRUGS OF FUSED-BICYCLIC C5aR ANTAGONISTS | C5AR2, C5AR1, C3AR1 | CES2 2296/4885HCAR1 27/4885ERN1 3801/4885 |
| US-20220378816-A1 | 2-BENZYLIDENE HYDRAZINOADENOSINE COMPOUNDS HAVING A2A ADENOSINE RECEPTOR AGONISTIC ACTIVITY | ADORA2A, ADORA1, ADORA3 | CES2 1511/4885HCAR1 51/4885ERN1 3209/4885 |
| US-20170143700-A1 | SYNTHESIS OF (R)-N-METHYLNALTREXONE | OPRM1, OPRL1, OPRK1 | CES2 1194/4885HCAR1 488/4885ERN1 2390/4885 |
| US-20130072467-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | ESRRA, ESRRB, ESR2 | CES2 2930/4885HCAR1 904/4885ERN1 134/4885 |
| US-20060079554-A1 | Inhibitors of monomine uptake | SLC6A2, SLC18A2, SLC6A3 | CES2 288/4885HCAR1 679/4885ERN1 3865/4885 |
| US-20140342221-A1 | PROCESS FOR THE MANUFACTURE OF 1, 1'-DIFLUOROSUBSTITUTED DIALKYL CARBONATES, ISOMERS THEREOF AND ELECTROLYTE COMPOSITIONS CONTAINING THEM | ADH1C, ADH1A, ALDH1A1 | CES2 894/4885HCAR1 2578/4885ERN1 1907/4885 |
| US-12448388-B2 | PRMT5 inhibitors and uses thereof | PRMT5, PRMT1, PRMT9 | CES2 4100/4885HCAR1 3964/4885ERN1 1469/4885 |
| US-20170360801-A1 | BROMODOMAIN INHIBITOR AS ADJUVANT IN CANCER IMMUNOTHERAPY | BRDT, BRD4, BRD1 | CES2 3748/4885HCAR1 2266/4885ERN1 3348/4885 |
| US-11485737-B2 | Diaryl substituted 5,5-fused ring compounds as C5aR inhibitors | C5AR1, C5AR2, C3AR1 | CES2 4329/4885HCAR1 97/4885ERN1 3845/4885 |
| US-10016394-B2 | PPARG modulators for treatment of osteoporosis | PPARG, PPARA, PPARD | CES2 4834/4885HCAR1 466/4885ERN1 1891/4885 |
| US-10829485-B2 | ATF6 inhibitors and uses thereof | ATF4, XBP1, ATF1 | CES2 2791/4885HCAR1 3887/4885ERN1 13/4885 |
| US-10828285-B2 | Diaryl substituted 6,5-fused ring compounds as C5aR inhibitors | C5AR1, C5AR2, C3AR1 | CES2 4257/4885HCAR1 82/4885ERN1 3863/4885 |
| US-10683294-B2 | 5-5 fused rings as C5a inhibitors | C5AR1, C5AR2, C3AR1 | CES2 4619/4885HCAR1 152/4885ERN1 3906/4885 |
| US-20100028301-A1 | IMIDAZO[4,5-c]PYRIDINE COMPOUNDS AND METHODS OF ANTIVIRAL TREATMENT | CYP3A5, TPMT, ZC3HAV1 | CES2 515/4885HCAR1 2643/4885ERN1 1050/4885 |
| US-20020013500-A1 | Process for producing trifluoromethylbenzylamines | MAOB, CYP2F1, AGL | CES2 449/4885HCAR1 3875/4885ERN1 843/4885 |
| US-20140011862-A1 | Compositions and Methods for Treating Leukemia | MCL1, ABL1, FLT3 | CES2 745/4885HCAR1 1886/4885ERN1 3841/4885 |
| US-20070219193-A1 | ALKYLAMINE-SUBSTITUTED BICYCLIC ARYL COMPOUNDS USEFUL AS MODULATORS OF PPAR | PPARG, PPARA, PPARD | CES2 526/4885HCAR1 193/4885ERN1 3166/4885 |
| US-20070244148-A1 | Imidazo 4,5-C Pyridine Compounds and Methods of Antiviral Treatment | ZC3HAV1, TPMT, DPP4 | CES2 1038/4885HCAR1 2835/4885ERN1 1174/4885 |
| US-20210221803-A1 | ATF6 INHIBITORS AND USES THEREOF | ATF4, XBP1, ATF1 | CES2 2791/4885HCAR1 3887/4885ERN1 13/4885 |
| US-20070259936-A1 | Benzimidazole Modulators of VR1 | VRK1, VRK2, VIL1 | CES2 2350/4885HCAR1 469/4885ERN1 2025/4885 |
| US-20210009596-A1 | DIARYL SUBSTITUTED 5,5-FUSED RING COMPOUNDS AS C5aR INHIBITORS | C5AR1, C5AR2, C3AR1 | CES2 4329/4885HCAR1 97/4885ERN1 3845/4885 |
| US-20210052612-A1 | PRODRUGS OF FUSED-BICYCLIC C5aR ANTAGONISTS | C5AR2, C5AR1, C3AR1 | CES2 2296/4885HCAR1 27/4885ERN1 3801/4885 |
| US-20230115912-A1 | DIARYL SUBSTITUTED 6,5-FUSED RING COMPOUNDS AS C5aR INHIBITORS | C5AR1, C5AR2, C3AR1 | CES2 4257/4885HCAR1 82/4885ERN1 3863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.